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ABSTRACT - In the past few years, the monoclonal antibody MIB-1 has been used by researchers in order to
retrospectively study paraffin imbibed tumor fragments. The medulloblastoma is the most common malignant
central nervous system tumor in childhood. The objectives were: determination of the mean Mib-1 LI value
from these patients, as well as the prognostic value of the method.This retrospective study represents an
analysis of the cellular proliferation index of posterior fossa medulloblastomas collected from 22 patients at
A.C. Camargo Hospital, from January 1990 to December 1999. The histopathological diagnosis was confirmed
by H&E and proliferative index (LI) was achived with Mib-1 which detects proliferating cells during G1, G2, S
and M phases.The results demostrated that the mean Mib-1 was 30,1%, and ranged from 5,2% to 62,0%.In
conclusion, this method has prognostic value, has to be used as routine for patients harboring medulloblastomas
and the ones who have PI greater than the mean value found in this study, should be treated aggressively.
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Meduloblastoma: avaliação do padrão proliferativo pelo anticorpo monoclonal Mib-1, correlação
prognóstica e implicações terapêuticas
RESUMO - Nos últimos anos, o anticorpo monoclonal Mib1 tem sido bastante utilizado pelos pesquisadores
para estudo retro e prospectivo, pela possibilidade de se obter um índice de proliferação de fragmentos
tumorais conservados em parafina. O meduloblastoma é o tumor maligno mais freqüente do sistema nervoso
central na infância. Os objetivos do trabalho foram determinar a média IP através do Mib-1 destas neoplasias,
e estabelecer seu valor prognóstico. Neste trabalho foi determinado retrospectivamente o índice de proliferação
celular de tumores extraídos de 22 pacientes portadores de meduloblastoma da fossa craniana posterior,
tratados no Departamento de Neurocirurgia do Hospital A.C. Camargo de S. Paulo, no período de janeiro de
90 a dezembro de 99. O diagnóstico histopatológico de meduloblastoma foi confirmado pela coloração pela
hematoxilina e eosina (HE) e o IP foi determinado através do marcador tumoral anticorpo monoclonal Mib1,
que detecta as células em proliferação tumoral nas fases G1, G2, S e M do ciclo celular. Os resultados mostraram
que a média do IP Mib1 foi de 30,1%, e variou de 5,2% a 62,0%. A conclusão é que este método tem valor
prognóstico, deve ser realizado como rotina no diagnóstico anatomopatológico dos pacientes portadores de
meduloblastoma e que aqueles com IP Mib1 maior que a média deverão ser submetidos a tratamentos
adjuvantes mais agressivos.
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The behaviour of a brain neoplasm is not
predictable by routine pathological diagnosis. Many
parameters are involved in order to analize the
biological behaviour of a brain tumor, however the
proliferative index evaluated by MIB-1 has been
applied to different types of brain neoplasm with
important prognostic correlation1-7. MIB -1 is a
monoclonal antibody (ma) which binds to a nucleolar
proteins in the proliferative cell receptors, in all steps
of the celular cycle, except in Go phase8. There are
not many papers correlating both the medullobas-
toma and the MIB-1 proliferation index (LI)9-15.
548 Arq Neuropsiquiatr 2003;61(3-A)
We sampled restropectively 22 surgical cases of
posterior fossa medulloblastoma, whose both clinical
data and pathological specimens were available and
analized immunohistochemically by means of the
MIB-1. The LI were studied taking in concern their
clinical prognosis.
METHOD
Clinical, surgical records and adjuvant treatment -
This study included 22 cases with histologically pro-
ven medulloblastomas, that were surgically treatead
from January 1990 to December 1999, for which
paraffin blocks were available. There were 13 male
and 9 female patients. Patient age ranged from 2 to
39 years with a mean of 12,1% years ( standart de-
viation SD = 11.66 ). The diagnostic was made on
average about 3 months after the first symptom.
The pre - operative clinical condition of the patients
was analyzed: 21 cases with high intracranial hyper-
tension (ICH) and 1 with convulsive syndrome. Cere-
bellar syndrome was found in 17cases. Regarding
the grade of resection: 12 were submitted to a total
resection, 8 subtotal resection and 2 partial resection.
Preoperative ventricle peritoneal shunting (VPS) was
performed in 8 patients and 2 patients were
submitted to a post operative VPS.
Pathological materials - All paraffin blocks used
in this study were obtained from surgical specimens.
Routine histologic types were reclassified, according
to the World Health Organization system (WHO). Fi-
gure 1 (Case 4), shows the characteristic aspect of a
medulloblastoma on routine diagnosis hematoxylin
and eosin (HE), with small round cells and compact
nucleus and pseudo-rosettes.
Immunohistochemical method and MIB - 1
staining index - Histological and immunohistoche-
mical studies were performed on paraffin sections.
Formalin fixed three mm sections were stained by
hematoxylin and eosin and also by immunohisto-
chemistry with monoclonal anti Ki-67 antigen clone
Mib1 (Immunotech, catalog number 0505, France)
using streptavidin-biotin-peroxidase complex tech-
nique. After deparaffinized and rehydrated, antigen
retrieval was performed using 10 mM pH 6,0 citrate
buffer solution in pressure cooker. Endogenous pero-
xidase activity was quenched by 3% H2O2. Sections
were incubated overnight at 40 C with antibody Mib-
1 diluted 1:100 in 1% bovine serum albumin and
phosphate buffered solution (PBS). Slides were then
incubated for 30 min at 370 C with biotinylated goat
anti-mouse/rabbit Ig, followed by incubation for
another 30 min at 370 C with the complex, strepta-
vidin and biotinylated peroxydase (StreptABComplex/
HRP Duet, Dako, k492, USA). The color reaction was
developed with 3,3’ diaminobenzidine tetrahydro-
chloride (Sigma, D-5637, USA), 6% H2O2 and PBS.
Fig 1. Case 2. Routine diagnostic with Hematoxilin and Eosin (H&E) in case of Medulloblastoma. The pseudorosetes
could be vizualized (400 X).
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Fig 2. Case 15. Immunohistochemical analisys with MIB-1. Higher density of labeled cells. The Mib 1was 35.50% (DAB)(400X).
Fig 3. Case 6. Immunohistochemical analysis with MIB-1. Lower density of labeled cells .The Mib 1was 16.80%  (DAB) (400X).
Sections were counterstained with Harris hema-
toxylin, dehydrated and coverslipped. Positive and
negative controls were included in this run.
The cell was classified positive when either the
entire nucleous or a portion of the nucleous was
stained. The number of positive and negative cells
were scored in a total of 1,000 cells per section, by
means of ocular grid under high power magnification
(X 400), the entire section was examined. The
labeling index (LI) or growth fraction was defined as
the proportion of positive cells in relation to total of
1,000 cells evaluted (excluding labeled endothelial
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cells and lymphocytes). One reading was performed
for each section in the 10 high power fields. The
average LI (LI mean - individual case) was obtained
by adding all labeled cells and dividing by 100. Figu-
res 2 and 3 show the labeled cells in the higher power
field of a higher density of proliferative cells and lo-
wer density of proliferative cells.
Evaluation of preoperative computerized tomo-
graphy (CT) - The authors reviewed the preoperative
CT in order to determine the tumour location and
hydrocephalus. The location of the tumors were: 16
cerebellar midline and 6 hemisphericals. There were
21 cases with obstructive ventriculomegaly.
Evaluation of adjuvant treatment - Radiotherapy
and chemotherapy were used in 14 patients. Che-
motherapy without radiotherapy was necessary in 5
patients. Radiotherapy without chemotherapy only
2 patients. One patient had no adjuvant treatment
due to death in the first postoperative month.
Survival period and follow up - The survival time
was 0.1 to 8.6 years (average = 3.8 years). After 10
years, only 7 patients were alive.
Statistical method - Data was entered into a da-
tabase on a personal computer and analyzed using
a statistical program. The chosen gold standard is
the MIB - 1 LI. To verify the correlation of the MIB - 1
with the clinical outcome (multiple comparison) sta-
tisticals analyses were used including the Mann-
Whitney (2 averages), or Kruskal-Wallis (3 or more
averages). The Survival period was analyzed by means
of Kaplan Meier and the logrank test comparison
between the mathematical curves of survival.
Statistical significance was determined at a p value
below 0.05.
RESULTS
Proliferative index (MIB-1LI) - The MIB-1 LI of all
patients are found on Table 1. The mean MIB-1 LI
was 30.1% (ranged from 5.2 to 62.0%, SD=13.9%).
MIB-1 LI and survival - The patients with MIB-1LI
with values from 5.2 to 30.1% showed probability
of survival of 71% in one year, 64% in 3 years and
49% in 5 years. The patients with values higher than
30.1% showed probability of survival of 75% in 1
year, 16% in 3 years and 0% in 5 years since the
beginning of treatment. (p=0.0367). This data is
summarized on Table 2.
DISCUSSION
Medulloblastoma is the most common solid tu-
mor in childhood, showing an incidence of 25 % in
the group of brain tumors at this age. In the past
ten years this incidence has been decreasing as des-
cribed by many authors. The cause of this remains
still unknown16. According to the literature review,
the probability of survival after 5 year-treatment is
lower in the high risk group than in the low risk group
of patients17. The higher risk group of patients is
under 3 years-old, partial resection tumor, spreading
tumor with metastasis in the central nervous
system18. Rutka and co-workers16 found 80% of 5-
year -survival rate in the low risk patients and 40%
in the high risk patients. In our series we have found
48% of 5-year-survival rate and 0% of 5 year-survival
rate respectively.
The mean MIB-1 LI found in literature was 20.9
(ranged from 13.1 to 30.9%)10-14. The present study
showed a mean MIB-1LI of 30.10% (ranged 5.2 to
60.0%). Our mean MIB-1 LI was higher than the
Table 2. Comparison between MIB-1LI and period of survival in
medulloblastomas.
Period of Survival 1 year 3 year 5 year
MIB-1 LI < 30.1% 71% 64% 49% Probability (%)
MIB-1 LI > 30.1% 75% 16% 0% Probability (%)
p=0.0367
Table 1. Labeling index of medulloblasmas analisys of 22 cases.
Patient MIB-1 LI (%) Patient MIB-1 LI (%)
1 27.2 (%) 12 44.8 (%)
2 25.0 (%) 13 25.4 (%)
3 7.2 (%) 14 39.0 (%)
4 28.0 (%) 15 35.5 (%)
5 27.6 (%) 16 16.9 (%)
6 16.8 (%) 17 5.2 (%)
7 26.5 (%) 18 44.8 (%)
8 22.1 (%) 19 62.0 (%)
9 24.7 (%) 20 41.0 (%)
10 20.7 (%) 21 46.3 (%)
11 26.8 (%) 22 44.80 (%)
Mean 30.1 (%), SD 13.9 (%).
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literature reviewed due probably to differences of
the immunohistochemical methods, and because we
used 10 fields with higher grade of labeled cells
which could increase the number of labeled cells on
avarege.
It seems that a patient harboring a medulloblas-
toma with higher MIB1 LI should have a worse prog-
nosis than a patient with lower, however it has never
been proved before on literature with a significant
number of patients. Ito and co-workers15 described
a similar relationship between Li and prognosis, al-
though no significant statistical support was found
by others13,14,19.
The definition of risk criteria for survival in me-
dulloblastoma is still controversial17,18,20.The fourth
floor ventricle invasion by the tumour was taken in
concern by Bailey and co-workers17, associated to
other risks listed above, neverthless we could suggest
formally the inclusion of MIB-1LI as a strong factor
of predictable risk.
In light of above the MIB-1 LI is a prognostic factor
regarding patients with medulloblastoma. This me-
thod should be employed routinelly in the group of
patients harboring medulloblastomas, and the ones
who have MIB-1 LI greater than 30.1% ought to be
treated aggressively.
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